Core Viewpoint - The company plans to acquire a 29% stake in Giant Biopharmaceutical Co., Ltd. from Enbip Pharmaceutical Co., Ltd. for 1.1 billion yuan, increasing its ownership in Giant Biopharmaceutical from 51% to 80% [1] Group 1: Transaction Details - The transaction involves a cash purchase of 1.1 billion yuan for the 29% stake in Giant Biopharmaceutical [1] - Upon completion of the transaction, the company's stake in Giant Biopharmaceutical will rise from 51% to 80% [1] Group 2: Strategic Implications - The acquisition aligns with the company's strategic shift towards the biopharmaceutical innovation sector, aiming to establish a leading innovative biopharmaceutical platform [1] - Giant Biopharmaceutical has developed a competitive R&D system and a promising product pipeline in the biopharmaceutical innovation field, with significant progress in the development and commercialization of multiple products [1] - The company views Giant Biopharmaceutical as a crucial growth engine and believes that acquiring the minority stake will enhance its business layout, implement its development strategy, and promote sustainable growth [1]

Core Viewpoint - The company intends to acquire a 29% stake in Giant Stone Biopharmaceutical Co., Ltd. from Enbip Pharmaceutical Co., Ltd. for 1.1 billion yuan, increasing its ownership from 51% to 80% [1] Group 1: Transaction Details - The transaction involves a cash purchase of 1.1 billion yuan for the stake in Giant Stone Biopharmaceutical [1] - Upon completion, the company's stake in Giant Stone will rise to 80% [1] Group 2: Strategic Implications - The acquisition aligns with the company's strategic shift towards the biopharmaceutical innovation sector, aiming to establish a leading innovative biopharmaceutical platform [1] - Giant Stone has developed a competitive R&D system and a promising product pipeline in the biopharmaceutical innovation field, with significant progress in the development and commercialization of multiple products [1] - The company views Giant Stone as a crucial growth engine and believes that acquiring the minority stake will enhance its business layout, implement its development strategy, and promote sustainable growth [1]

Group 1 - The company Xinnoway (300765.SZ) signed a share transfer agreement with Enbipu Pharmaceutical to acquire a 29% stake in Jushi Biotech for a cash consideration of 1.1 billion yuan, increasing its ownership from 51% to 80% [1] - The transaction is based on an asset evaluation report from a qualified institution as per the Securities Law [1] Group 2 - Jushi Biotech is an innovative biopharmaceutical company focused on antibody drugs, antibody-drug conjugates (ADC), and mRNA vaccines, with a strong emphasis on independent research and development [2] - The company has a comprehensive R&D and commercialization capability, covering three major therapeutic areas: oncology, autoimmune diseases, and major infectious diseases [2] - Jushi Biotech has numerous projects in development, with key products like Enlansumab and Omabuzumab expected to launch in 2024, and several others in critical clinical trial phases [2] - The company has established itself as a benchmark in the domestic monoclonal antibody and ADC innovation drug industry, providing safe, effective, and accessible biotherapy solutions globally [2] - Jushi Biotech is among the first domestic companies to achieve mRNA vaccine commercialization and has a complete pipeline for ADC and monoclonal antibodies [2]

Group 1 - The company Xinnoway (300765.SZ) signed a share transfer agreement with Enbipu Pharmaceutical to acquire a 29% stake in Jushi Biotech for a cash consideration of 1.1 billion yuan, increasing its ownership from 51% to 80% [1] - The transaction is based on an asset evaluation report from a qualified institution in accordance with the Securities Law [1] Group 2 - Jushi Biotech is an innovative biopharmaceutical company focused on antibody drugs, antibody-drug conjugates (ADC), and mRNA vaccines, with a strong emphasis on independent research and development [2] - The company has established a competitive R&D system and a promising product pipeline, covering three major therapeutic areas: oncology, autoimmune diseases, and major infectious diseases [2] - Jushi Biotech has numerous projects in development, with key products like Enlansumab and Omabuzumab set to launch in 2024, and several others in critical clinical trial phases [2] - The company has become a benchmark in the domestic monoclonal antibody and ADC innovation drug industry, providing safe, effective, and accessible biotherapy solutions globally [2] - Jushi Biotech is one of the first domestic companies to achieve mRNA vaccine industrialization and has a comprehensive layout in ADC and monoclonal antibody pipelines [2]

新诺威9月30日公告，公司拟以现金方式购买石药集团恩必普药业有限公司持有的石药集团巨石生物制 药有限公司29%股权，交易价款为11亿元。本次交易完成后，公司持有巨石生物的股权比例将由51%增 加至80%。 ...

（记者 贾运可） 每经AI快讯，新诺威9月30日晚间发布公告称，公司拟以现金购买恩必普药业持有的巨石生物29%股 权。本次交易以符合《证券法》规定的评估机构出具的资产评估报告中的评估结果作为定价依据，最终 确定本次交易标的股权的转让价款为110000万元。本次交易完成后，公司持有巨石生物的股权比例将由 51%增加至80%。 每经头条（nbdtoutiao）——前脚消费贷，后脚被银行追讨发票，7天内上传，否则后果严重！有人为此 焦虑，有人却趁机牟利：帮开票包过审 ...

证券代码：300765 证券简称：新诺威 公告编号：2025-074 石药创新制药股份有限公司 关于现金收购控股子公司石药集团巨石生物制药有限公司 部分少数股权暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、石药创新制药股份有限公司（以下简称"公司"、"上市公司"、"石药创新"） 拟以现金购买石药集团恩必普药业有限公司（以下简称"恩必普药业"）持有的石 药集团巨石生物制药有限公司（以下简称"巨石生物"或"标的公司"）29%股权（以 下简称"本次交易"）。本次交易完成后，公司持有巨石生物的股权比例将由 51% 增加至 80%。 2、本次交易以符合《证券法》规定的资产评估机构出具的资产评估报告中 的评估结果作为定价依据，最终确定本次交易标的股权的转让价款为 110,000.00 万元。 | | 本次交易前 | | | 本次交易后 | | | --- | --- | --- | --- | --- | --- | | 股东 | 出资额（万元） | 持股比例 | 股东 | 出资额（万元） | 持股比例 | | 石药创新 | 104,0 ...

Group 1 - The core point of the news is that XinNuoWei's stock price has been declining, with a total drop of 9.61% over the last three days, closing at 46.47 CNY per share on September 29, with a market capitalization of 65.271 billion CNY [1] - XinNuoWei's main business involves the research, production, and sales of functional foods, which account for 88.93% of its revenue, while biopharmaceuticals contribute 8.91% and other sources 2.16% [1] - The company is located in Shijiazhuang, Hebei Province, and was established on April 5, 2006, with its listing date on March 22, 2019 [1] Group 2 - According to data from the top ten holdings of funds, one fund under JiaoYin ShiLuoDe has a significant position in XinNuoWei, specifically the JiaoYin Medical Innovation Stock A fund, which reduced its holdings by 651,000 shares in the second quarter [2] - The JiaoYin Medical Innovation Stock A fund currently holds 2.3373 million shares of XinNuoWei, representing 4.66% of the fund's net value, making it the fifth-largest holding [2] - The fund has experienced a floating loss of approximately 3.0853 million CNY today and a total floating loss of 11.5464 million CNY during the three-day decline [2]

Market Overview - On September 25, the A-share market experienced fluctuations, with the ChiNext Index rising over 2% at one point, reaching a three-year high. The Shanghai Composite Index closed down 0.01%, while the Shenzhen Component Index rose by 0.67% and the ChiNext Index increased by 1.58% [2][3] - The total trading volume in the Shanghai and Shenzhen markets was 2.37 trillion yuan, an increase of 44.3 billion yuan compared to the previous trading day [2] Sector Performance - The gaming, AI applications, and controllable nuclear fusion sectors saw significant gains, while the port shipping, precious metals, and oil and gas sectors experienced declines [2] International Market - The U.S. stock market indices collectively fell on September 25, with the Dow Jones Industrial Average down by 173.96 points (0.38%), closing at 45,947.32 points. The S&P 500 dropped by 33.25 points (0.50%) to 6,604.72 points, and the Nasdaq Composite fell by 113.16 points (0.50%) to 22,384.70 points [4][5] - European markets also saw declines, with the FTSE 100 down 0.39%, the CAC 40 down 0.41%, and the DAX down 0.56% [4][5] - International oil prices slightly decreased, with WTI crude oil closing at $64.98 per barrel (down 0.02%) and Brent crude oil at $69.42 per barrel (up 0.16%) [4][5] Digital Currency Development - The Digital Renminbi International Operation Center officially commenced operations, introducing three major business platforms aimed at enhancing cross-border payment systems and financial infrastructure [7] Copper Industry Insights - The China Nonferrous Metals Industry Association is accelerating research on how to strengthen the standardized management of copper smelting capacity, addressing issues of excessive competition and low processing fees in the copper industry [8][9][10] Policy Changes - Guangzhou has introduced new policies allowing real estate companies to sell self-held housing after paying the necessary fees, aimed at improving land utilization efficiency [13] - The Chinese Foreign Exchange Trading Center announced an increase in the daily net limit for the "Swap Connect" mechanism to 45 billion yuan starting October 13 [11] Company Announcements - Xiaomi launched its new Xiaomi 17 series smartphones, starting at a price of 4,499 yuan [12] - Several companies, including Shanghai Electric and Inspur Information, saw significant net inflows of capital, indicating strong market interest [18][20]

Group 1: Regulatory Actions - The National Healthcare Security Administration (NHSA) has launched a "100-day action" to address prominent issues in medical insurance fund management, aiming to combat fraud and illegal activities related to the resale of medical insurance drugs [1] - The initiative reflects a zero-tolerance approach towards fraudulent practices, which may increase compliance pressure on medical institutions and pharmaceutical companies in the short term, while potentially purifying the industry ecosystem in the long run [1] Group 2: Company Developments - Hanyu Pharmaceutical plans to raise up to 968 million yuan (approximately 136 million USD) through a private placement to fund various projects, including the research and development of Semaglutide [2] - The approval of Lunacanab by XinNuoWei for clinical trials marks the first domestic biosimilar drug for Alzheimer's disease, which could enhance patient accessibility and alleviate financial burdens [3] - Baile Tianheng's ADC dual antibody, Iza-bren, has been included in the breakthrough therapy list by the National Medical Products Administration, which may expedite its market entry and positively impact the company's stock price [4] - Tainkang's subsidiary has received approval for clinical trials of CKBA cream for rosacea, filling a gap in the domestic market for innovative treatments in this area [5]